Therapist Skepticism and Adaptation to Teletherapy Under Enforced Uptake, With Theoretical Considerations for AI-Mediated Care: Qualitative Study

<strong>Background:</strong> Mental health care is undergoing rapid digital transformation, with continued development and implementation of digitally delivered interventions. Despite growing evidence for digital mental health interventions, implementation in routine practice has often lagged technological advances. Although teletherapy became more widely accepted during the COVID-19 pandemic, little is known about the psychological processes through which clinicians adapt to disruptive changes in treatment delivery when required to work within a novel medium. <strong>Objective:</strong> This study explored how therapists who had not previously adopted teletherapy interpreted and adapted to its enforced uptake during the COVID-19 pandemic, with particular attention to changes in expectations, perceptions of the therapeutic alliance, and professional practice. <strong>Methods:</strong> Six UK-based accredited clinical psychologists, none of whom had previously practiced video-based teletherapy, participated in semistructured interviews conducted between May and July 2021, following the rapid shift toward remote delivery. Data were analyzed using reflexive thematic analysis to explore therapists’ experiences of adaptation, belief revision, and therapeutic interactions. <strong>Results:</strong> We identified the following four themes: (1) revision of anticipatory beliefs, (2) context-medium differentiation, (3) medium affordances, and (4) relational viability and selective integration. Therapists began practicing teletherapy with concerns about accessibility, safety, therapeutic techniques, and relational quality. With sustained practice, clinicians revised many of their assumptions. Therapists also distinguished difficulties associated with implementation contexts from perceived properties of teletherapy itself. They described adapting clinical procedures and techniques, recognizing both constraints and affordances of the medium, and developing more differentiated views of when teletherapy was appropriate. Clinicians generally found teletherapy to be an acceptable therapeutic medium, but not equivalent to in-person practice. <strong>Conclusions:</strong> Adapting to teletherapy involved more than accepting a new tool. It required therapists to reconsider assumptions about therapeutic interaction, safety, and conditions needed to sustain an effective therapeutic relationship. The findings suggest an experience-based professional adaptation process in which initial assumptions became differentiated through sustained use. While these findings support teletherapy uptake specifically, they may also inform how clinicians evaluate other digital mental health technologies, while recognizing that changes to the communication medium are not equivalent to changes in the therapeutic process or agent.

An Evidence-Based AI Virtual Assistant for Young People With Attention Deficit Hyperactivity Disorder: Co-Design and Prototype Development

<strong>Background:</strong> Though attention deficit hyperactivity disorder (ADHD) is thought to be the most prevalent neurodevelopmental disorder in young people worldwide, there are inequalities in access to psychoeducation and health care support. One way to improve access, potentially increase engagement, reduce health care inequalities, and enhance care is by co-developing digital responsive interventions. These have the potential to support long-term condition management and to act as an adjunct to usual care. Virtual assistants that use large language models can provide information in response to questions and learn to tailor communication to suit an individual user’s needs. This can be especially valuable for people with ADHD who often struggle to regulate attention and can experience communication challenges. Involving people with lived experience in the co-design process is crucial for the development of effective digital interventions. Therefore, this article explores the views and preferences of young people with ADHD and their supporters from the United Kingdom who collaborated with researchers to co-design a prototype chatbot. <strong>Objective:</strong> This study aimed to co-develop an evidence-based chatbot prototype, intended to help young people with ADHD thrive through improved access to health care information, psychoeducation, and self-management strategies. <strong>Methods:</strong> An interdisciplinary team was established, including researchers, software developers, clinicians, and lived experience collaborators. Research advisory and working groups were set up in ways that facilitated flexible involvement. Following the person-based approach, guiding principles were established, and workshops were held with young people with ADHD and supporters of young people with ADHD to co-develop an early prototype. Feedback was sought via think-aloud interviews with lived experience collaborators. <strong>Results:</strong> In total, 9 experts by lived experience and 3 health care professionals chose to engage in workshops, and this feedback informed the development of a SmartADHD chatbot prototype. An off-the-shelf chatbot (GPT-4o hosted on Convai) was trained using resources from the National Health Service (NHS). Overall, 6 experts by lived experience engaged with think-aloud interviews, providing feedback on the prototype conversational flow and feel, the avatar, the text-to-speech, the chatbox feature, and the content of the messages. Seven recommendations are made for future development, which will inform the SmartADHD program of work. <strong>Conclusions:</strong> These findings provide rich data on the preferences of people with ADHD. Specific recommendations for a chatbot for young adults with ADHD have not been investigated before with young people, making this study a novel contribution to the field. These findings provide an excellent foundation for chatbot development for this group and may be relevant for those developing digital tools for people with ADHD across the lifespan and other neurodevelopmental conditions. Further work is required to elucidate the views of health care professionals and identify the limits of the technology before subsequent evaluation. <strong>Trial Registration:</strong>

Remotely Supervised, Home-Based Transcranial Direct Current Stimulation for Major Depressive Disorder: Systematic Review and Meta-Analysis

Background: Major depressive disorder affects over 280 million people worldwide, and access to effective treatment remains limited. Transcranial direct current stimulation (tDCS) is a noninvasive option, and portable devices now allow for home-based delivery under varying degrees of remote supervision. Objective: This study aimed to systematically review and meta-analyze the efficacy, safety, feasibility, and acceptability of home-based and remotely supervised tDCS for depressive disorders. Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 and PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses literature search extension) guidelines, we searched MEDLINE, Embase, Web of Science, the Cochrane databases, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to July 2025, with backward and forward citation searching. Two reviewers independently screened records, extracted data, and assessed risk of bias (version 2 of the Cochrane risk-of-bias tool for randomized trials, Newcastle-Ottawa Scale for observational studies, and Critical Appraisal Skills Programme for qualitative studies) and certainty of evidence (Grading of Recommendations Assessment, Development, and Evaluation; GRADE). Results: This review included 12 distinct studies (16 reports), of which 6 (50%) were randomized sham-controlled trials forming the meta-analytic pool. Active home-based tDCS produced a small, statistically significant improvement over sham (pooled Hedges =0.36, 95% CI 0.06-0.66; =.03; =34.3%). The effect was not robust to removal of the single largest positive trial (omitting the one study from 2025: =0.39, 95% CI −0.12 to 0.91), and trial-level results were mixed: the 2 largest trials (one unsupervised [n=210] and one self-administered [n=141]) were negative on their primary depression outcomes, whereas the largest real-time supervised trial (n=174) was positive (between-group 95% CI 0.51‐4.01; =.01). This estimate was concordant in direction with an independent peer-reviewed meta-analysis of overlapping trials, which reported a pooled Montgomery-Åsberg Depression Rating Scale reduction (weighted mean difference −2.74, 95% CI −4.19 to −1.29) and Hamilton Depression Rating Scale reduction (weighted mean difference −2.24, 95% CI −4.16 to −1.49), attenuating to nonsignificance (>.05) in major depressive disorder without comorbid cognitive impairment. The pooled effect fell at or near the minimal clinically important difference. GRADE certainty was moderate. Adverse events were predominantly mild: one pilot study was terminated early for skin lesions, and one nonfatal suicide attempt occurred in an unsupervised trial. Conclusions: Home-based and remotely supervised tDCS produces a small, statistically significant but clinically modest antidepressant effect that is sensitive to the inclusion of the largest positive trial, with the 2 largest trials being negative. The available controlled evidence does not establish supervision intensity as a determinant of efficacy. Current data are insufficient to recommend routine clinical adoption; adequately powered trials with standardized supervision and longer follow-up are needed. Trial Registration: PROSPERO registration number CRD420251109275; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251109275

INTEGRATING EXPOSURE AND RESPONSE PREVENTION AND HABIT REVERSAL TECHNIQUES TO TREAT A TOURETTIC SUBTYPE OF OBSESSIVE-COMPULSIVE DISORDER (TOURETTIC OCD).

Conditions: Obsessive – Compulsive Disorder; Tic Disorder, Chronic Motor or Vocal; Tic Disorders; Tic Disorder, Combined Vocal and Multiple Motor; Tourette Disease; Tourette Disorder; Tourettes Syndrome; Gilles de la Tourette Syndrome

Interventions: Behavioral: Exposure and Response Prevention (ERP); Behavioral: Habit Reversal Training (HbRT; Behavioral: Psychoeducation and Supportive Intervention

Sponsors: University College London Hospitals

Recruiting

Effects of visual art therapy on depressive symptoms in adults: a systematic review and meta-analysis

ObjectiveTo systematically evaluate the intervention effects of visual art therapy on depressive symptoms in adults, and to examine its impact on anxiety symptoms.MethodsA systematic search was conducted in databases including CNKI, WanFang Data, VIP, Chinese Biomedical Literature Database (CBM), PubMed, Web of Science, Cochrane Library, and Embase from inception to March 2026. Randomized controlled trials were included in which visual art therapy was used to intervene in depressive symptoms among adults (≥18 years).Meta-analysis was performed using Stata 18.0 software.The primary outcome was depressive symptoms, measured by scales such as the BDI, GDS, HADS-D, and SDS, and the secondary outcome was anxiety symptoms, measured by scales such as the BAI, HADS-A, and SAS. Fixed-effect or random-effect models were selected according to the level of heterogeneity, and subgroup analyses were conducted.ResultsA total of 12 randomized controlled trials involving 741 adults were included, with 377 participants in the intervention group and 364 in the control group.The meta-analysis showed that visual art therapy effectively alleviated depressive symptoms (SMD = -0.81, 95% CI: -1.16 to -0.46, P < 0.00001) and anxiety symptoms (SMD = -0.69, 95% CI: -0.90 to -0.48, P < 0.00001) in adults.Subgroup analyses indicated that interventions with a duration of <12 weeks, <12 sessions in total, and a single-session length of ≤60 minutes were associated with larger effect sizes for the improvement of depressive symptoms; improvements in anxiety symptoms were more pronounced in intervention protocols characterized by higher frequency (>12 sessions), shorter overall duration (≤6 weeks), and shorter single-session length (≤60 minutes).ConclusionAs a non-pharmacological intervention, VAT has potential as an adjunctive approach for alleviating depressive and anxiety symptoms in adults.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261371354, identifier CRD420261371354.

Effects of exercise interventions on executive function in autism spectrum disorder: a three-level meta-analytic review

ObjectiveThis study aimed to use a three-level meta-analysis to examine the effects of exercise interventions on executive function (EF) in children and adolescents with autism spectrum disorder (ASD), and to explore the relationship between exercise dose and intervention effects through subgroup analyses.MethodsA systematic search was conducted in Web of Science, PubMed, Embase, and the Cochrane Library from database inception to November 17, 2025. All included studies were randomized controlled trials. A three-level random-effects model was applied to integrate multiple dependent effect sizes. Hedges’ g was used to calculate effect sizes, and negative values indicated improvements in EF following exercise interventions. Study quality was assessed using the PEDro scale, and publication bias was evaluated using Egger’s regression and the trim-and-fill method.ResultsSeventeen studies involving 626 participants were included. Exercise interventions produced a moderate and significant improvement in EF (g = –0.34, p < 0.0001) with low heterogeneity (Q = 50.42, p =0.268). Subgroup analyses showed that only intervention duration significantly moderated the effects, with programs lasting ≥10 weeks yielding the greatest benefits.ConclusionExercise interventions significantly improve EF in children and adolescents with ASD, with the largest effect sizes observed in interventions lasting ≥10 weeks. Further large-scale studies are needed to clarify dose–response relationships and inform optimal exercise prescriptions. This meta-analysis was designed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251236112

Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study

Background: Social media is an increasingly prominent channel for communicating menopause information and experiences, yet the affective and behavioral consequences of different narrative framings remain unclear. Objective: We examined how distress, normalizing, and transformative narratives influenced women’s immediate responses to menopause content online, drawing on established narrative framings of menopause as normality, distress, and transformation. Methods: In an online experiment, UK women aged 40 to 83 years who were perimenopausal or postmenopausal were recruited via Prolific, a widely used online recruitment platform for behavioral and social science research. A total of 737 women were randomly assigned to view 4 anonymized and standardized social media posts from a pool of 12 reflecting 1 of 3 narratives: <i>normal</i> (n=248, 33.6%), <i>distress</i> (n=241, 32.7%), or <i>transformative</i> (n=248, 33.6%). Participants then reported affective reactions, expected behavioral responses, and perceptions of the posts using 5-point ordered response scales. Ordinal logistic regression models tested demographic predictors and condition effects controlling for demographic factors. Results: Participants who viewed distress-framed posts reported greater levels of worry (β=.910; <i>P</i><.001), confusion (β=.818; <i>P</i><.001), and anxiety (β=.817; <i>P</i><.001) and lower levels of reassurance (β=−.970; <i>P</i><.001), optimism (β=−.708; <i>P</i><.001), and empowerment (β=−.540; <i>P</i><.001). Distress framing also increased perceived knowledge of menopause (β=.564; <i>P</i><.001) despite participants feeling more negatively toward the posts. Neither distress nor transformative narratives influenced expected behavioral intentions to like, share, save, comment on, search for, or discuss social media posts compared with normalizing narratives. Postmenopausal status (β=−.630; <i>P</i><.001) and older age (β=−.492; <i>P</i><.001) were independently associated with less worry and anxiety. Participants rated distress (β=−.806; <i>P</i><.001) and transformative posts (β=−.968; <i>P</i><.001) as less representative of health professionals than normalizing posts; transformative posts were also judged to be less representative of newspapers or television (β=−.687; <i>P</i><.001). Conclusions: Narrative framing shaped immediate affect but not intended engagement with menopause content. Because this study assessed short-term responses to controlled, standardized posts, future research should examine whether these effects persist over time and how they operate in more ecologically valid social media environments. As public discussion expands, diverse, balanced narratives may help reduce stigma and temper the disproportionate salience of negative framing. This study advances understanding of how narrative framing shapes responses to health content online.

Pharmacotherapy, acupoint stimulation, and psychotherapy for perimenopausal women with anxiety, depression, and panic disorder: a systematic review and network meta-analysis of randomized controlled trials

BackgroundPerimenopausal women frequently experience physiological and psychological symptoms, including anxiety, depression, and panic disorders, mainly due to declining ovarian function and hormonal changes. Current options include pharmacotherapy, acupoint stimulation (AcuStim), and psychotherapy (psych), but their comparative efficacy and safety remain controversial.ObjectiveThis network meta-analysis (NMA) systematically compared pharmacotherapy, AcuStim, and psychotherapy for perimenopausal anxiety, depression, and panic disorder, assessing clinical efficacy, adverse events (AEs), and changes in the Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), Kupperman Index (KI), Self-rating Depression Scale (SDS), Self-rating Anxiety Scale (SAS), Pittsburgh Sleep Quality Index (PSQI), and serum hormone levels.MethodsWe searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, VIP, and SinoMed from inception to June 14, 2026, for randomized controlled trials (RCTs). A Bayesian NMA was performed, and the Surface Under the Cumulative Ranking Curve (SUCRA) was calculated.ResultsThe study included 131 RCTs, encompassing 11457 perimenopausal women diagnosed with emotional disorders. These trials evaluated three distinct treatment strategies. The NMA showed that the highest SUCRA probabilities were observed for drug_psych across HAMD (SUCRA = 92.4%), KI (SUCRA = 97.9%), SDS (SUCRA = 94.5%), PSQI (SUCRA = 98.1%), and follicle-stimulating hormone (FSH) (SUCRA = 96.1%) reduction and estradiol (E2) (SUCRA = 0.1%) elevation; for AcuStim_psych (SUCRA = 93.7%) in HAMA reduction; for psych (SUCRA = 98.9%) in SAS reduction; for drug_AcuStim in clinical efficacy (SUCRA = 9.0%) and luteinizing hormone (LH) reduction (SUCRA = 100%); and for control (SUCRA = 65.5%) in safety outcomes. In pharmacotherapy subgroup analyses, antidepressants (ADs)_Traditional Chinese medicine (TCM) ranked highest for HAMD (SUCRA = 87.2%) and safety (SUCRA = 82%), ADs_antipsychotics (AP) (SUCRA = 97.5%) for HAMA, and ADs_hormone replacement therapy (HRT) (SUCRA = 10.2%) for clinical efficacy.ConclusionPharmacological, acupoint stimulation, and psychological interventions each demonstrated therapeutic benefits for perimenopausal women with emotional disorders. Combination therapies generally showed more favorable efficacy across multiple psychological and endocrine outcomes than single-modality interventions, while no single treatment strategy was consistently superior across all outcomes. These findings may provide evidence to support individualized treatment selection according to patients’ clinical characteristics and therapeutic goals.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261340530.

Blood Test Foresees Decline into Alzheimer’s Disease

A blood-based biomarker could predict a person’s risk of developing Alzheimer’s disease years before any symptoms arise, research suggests.

Plasma levels of phosphorylated tau 217 (p‑tau217) may one day help identify at-risk individuals before overt signs of dementia, enabling the pre-emptive use of disease-modifying therapies.

Higher plasma p‑tau217 levels were associated with a greater risk of progressing to cognitive impairment in previously unaffected older adults, and they also predicted faster levels of decline.

The research findings appear in JAMA and were simultaneously presented this week at the annual Alzheimer’s Association International Conference in London.

“In this longitudinal study of several selected cohorts, plasma p-tau217 provided long-term prognostic information for individuals who were cognitively unimpaired at baseline, laying the groundwork for possible future development of individualized risk prediction scores,” proposed Rachel Buckley, PhD, from Mass General Brigham, and co-workers in their published work.

“By providing absolute risk estimates of progression to cognitive impairment, this article moves the field closer to presymptomatic risk stratification with p-tau217, supporting trial design.”

The large, pooled multicohort study included 2684 cognitively unimpaired older adults from six longitudinal studies, who were followed for a median of 5.4 years. Their median age was just short of 70 years, and 63% were women.

Results showed that higher baseline p-tau217 was significantly associated with an increased risk of progression to cognitive impairment during up to 13.5 years of follow up, with a hazard ratio of 1.38 per standard deviation (SD) increase.

This remained significant after accounting for age, sex, education, apolipoprotein E ε4 status, cohort, as well as amyloid positron emission tomography—known to accurately detect Alzheimer’s disease brain pathology.

The researchers report that the absolute risk of cognitive decline at five years was “meaningfully elevated” in the group with very high p-tau217 levels (≥2.5 SD) at 38%, versus just 12% in group with low levels.

Estimated 10-years risks were substantially higher at between 40% and 78% for the low and high p-tau217 groups, respectively. However, just 139 participants—or one in every 20—were followed up for at least a decade and the researchers say these risk estimates should be treated with caution.

Elevated p-tau217 was also associated with faster decline on the harmonized latent Preclinical Alzheimer Cognitive Composite assessment tool.

In an editorial accompanying the published study, Suzanne Schindler, PhD, from Washington University in St Louis school of medicine, and David Wolk, MD, from the University of Pennsylvania, note that cognitive impairment likely reflected multiple etiologies, not just Alzheimer’s disease.

“Indeed, even the low p-tau217 group, in which Alzheimer disease pathology was minimal or absent, still had a 12% risk of progression to cognitive impairment at five years, suggesting the importance of other drivers of cognitive decline in this population and the likelihood that in the higher p-tau217 groups, some proportion of individuals who declined may have primarily been driven by other processes,” they pointed out.

“Notably, discordance between plasma p-tau217 and amyloid PET (especially at intermediate or low amyloid levels) highlights that biomarkers beyond p-tau217 could further improve risk prediction.”

Nonetheless, overall they summarized: “The study by Buckley et al. represents a significant advance. It demonstrates that plasma p-tau217 can provide a time-specific absolute risk estimate for development of cognitive impairment.”

The post Blood Test Foresees Decline into Alzheimer’s Disease appeared first on Inside Precision Medicine.

Efficacy of digital interventions in social anxiety disorder: a systematic review and Bayesian network meta-analysis

BackgroundSocial anxiety disorder (SAD) is characterized by a significant and persistent fear of social or performance situations. The prevalence of SAD has gradually increased recently, and the unique advantages of digital interventions (DIs) have gained traction in psychiatric disorders. However, there is currently no comprehensive review comparing the effectiveness of diverse DIs for SAD.MethodsRandomized controlled trials (RCTs) evaluating DIs for patients with SAD were identified by searching the PubMed, Cochrane Library, and Embase databases from January 1, 1995, to March 31, 2025. The study protocol for this network meta-analysis was registered in PROSPERO. Data were analyzed via Bayesian framework network meta-analysis.ResultsForty-two RCTs were included. The results showed that DIs exerted better efficacy than non-digital interventions and wait-list controls (WLC). Different forms of internet-based cognitive behavioral therapy (ICBT) demonstrated robust effects across all four outcomes. Internet-based cognitive therapy (ICT) yielded favorable effects in reducing social anxiety and depressive symptoms. VR showed relatively large effect sizes for improving quality of life.ConclusionDIs can be recommended as adjunctive or combined treatments for SAD. Different forms of ICBT show consistent efficacy and can serve as the first-line option among digital interventions. We recommend promoting the application of DIs to expand treatment coverage for SAD and overcome the limitations of traditional psychotherapy.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251077835.